Here are four takeaways:
1. Four new patents were issued for the company’s amniotic membrane allograft product lines and eight for the company’s CollaFix technology platform.
2. Three of the 12 patents were issued to MiMedx since Nov. 1, 2015.
3. MiMedx is an integrated developer, processor and marketer of patent protected and proprietary regenerative biomaterial products and bioimplants.
4. It develops products and therapies for the wound care, surgical, orthopedic, spine, sports medicine, ophthalmic and dental markets.
More articles on devices:
5 key notes on minimally invasive SI joint fusion implant survivorship
5 key trends driving the spine & orthopedic device market development today
K2M, SeaSpine, Blue Belt & more: 18 key notes
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
